Drug Index


Mechanism :

Pancuronium is a nondepolarizing neuromuscular blocking agent. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.

Indication :

  • Neuromuscular blockade
  • Ventilation

Contraindications :

Contraindicated in patients known to have hypersensitivity to pancuronium bromide. Use with caution in severe renal impairment as duration of action is prolonged. Since pancuronium causes relaxation of the respiratory muscles, respiration must be assisted in all patients.

Dosing :

Neonates: IV loading 0.02 mg/kg followed by maintenance IV 0.05-0.1 mg/kg/dose every 30 mins to 4 hours, as and when needed.
1 month-18 years: 0.04-0.1 mg/kg IV initially followed by 0.015-0.01 mg/kg every half to one hour, OR continuous IV: 0.1 mg/kg/hr.

Adverse Effect :

Tachycardia, hypertension, excessive salivation, transient rashes, wheezing, histamine release.

Interaction :

Aminoglycosides, Metronidazole, Polymyxins, Suxamethonium, Nifedipine, Verapamil, Propranolol, Procainamide, Quinidine, Lithium and Parenteral Magnesium, High Doses of Thiopental, Ketamine, Fentanyl, Beta-Blockers and Diuretics: Enhanced effect.
Corticosteroids, Phenytoin and Carbamazepine: Decreased effect.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Initial dose: 25–50 micrograms/kg Incremental dose: 5–10 micrograms/ kg
<10Initial dose: 10–25 micrograms/kg Incremental dose: 2.5–5 micrograms/kg

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnknown dialysability. Dose as in GFR<10 mL/min
HDUnknown dialysability. Dose as in GFR<10 mL/min
HDF/High fluxUnknown dialysability. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in GFR=10–20 mL/min

Hepatic Dose :

Elimination half-life is doubled, plasma clearance is doubled, recovery time is prolonged, volume of distribution is increased (50%) and results in a slower onset, higher total dosage, and prolongation of neuromuscular blockade. Patients with liver disease may develop slow resistance to non-depolarizing muscle relaxant. Large doses may be required and problems may arise in antagonism.
03/18/2024 23:57:14 Pancuronium
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0